-
Mashup Score: 0RxPONDER: sparing chemotherapy in post-menopausal patients with node-positive early-stage breast cancer - 3 year(s) ago
The de-escalation and treatment personalization of patients with early breast cancer has advanced in recent years, with studies such as…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cancer Research: 81 (4 Supplement) - 3 year(s) ago
Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Exciting trial updates from the upcoming SABCS 2020 meeting - 3 year(s) ago
Cynthia X. Ma, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discussing upcoming studies to…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [HR−]) on clinical behavior and outcomes of mBRCA BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see in @Nature_NPJ our #SABCS20 data on clinical behavior & outcomes of #BreastCancer in #young women with germline #BRCA mutations: huge academic effort & important step to improve the care of these patients @OncoAlert #bcsm @SABCSSanAntonio https://t.co/6sp1aYtQn2 https://t.co/fGnZIxwgOs
-
-
Mashup Score: 2Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Highlights from SABCS 2020 - 3 year(s) ago
Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, discussing ongoing breast cancer clinical trials, including the ADAPT trial (NCT01779206), RxPONDER…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Next questions in breast cancer treatment - 3 year(s) ago
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the next questions in the treatment and management of breast…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advances in breast cancer coming in 2021 - 3 year(s) ago
Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany discusses the need for new drugs in the HER2-positive metastatic space in…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer? - The ASCO Post - 3 year(s) ago
Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-risk breast cancer, according to results of the large randomized PRIME II trial reported at the 2020 San Antonio Breast…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adding Entinostat to Exemestane Fails to Overcome Aromatase Inhibitor Resistance in Advanced Breast Cancer - The ASCO Post - 3 year(s) ago
The histone deacetylase inhibitor (HDAC) entinostat, added to exemestane, failed to overcome endocrine therapy resistance in advanced breast cancer, according to the E2112 phase III trial conducted by the ECOG-ACRIN Cancer Research Group. Results showed that overall survival was not improved by the combination of the two…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
📰 ARTICLE | RxPONDER: study results, impact on clinical practice and potential role of ovarian suppression Read it here: https://t.co/SsY5AkL0zc @VJOncology @OncoAlert @SABCSSanAntonio #SABCS20 #BreastCancer #BCsm #RxPONDER